Osteoarthritis Biomarkers Project (OABP)

At a Glance
  • Status: Completed Consortium
  • Year Launched: 2012
  • Initiating Organization: Foundation of the National Institutes of Health
  • Initiator Type: Nonprofit foundation
  • Disease focus:
    Arthritis
  • Location: International

Abstract

The Osteoarthritis Biomarkers Project (OABP) is a consortium designed to identify and classify biological markers of progression of knee osteoarthritis (OA). The goal is to advance the ability to predict an individual’s risk of developing severe OA and to monitor progression of OA, which would lead to early intervention.

Mission

As a partnership between the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium, NIH’s Osteoarthritis Initiative (OAI), and the Osteoarthritis Research Society International (OARSI), OABP’s goal is to identify one or more quantitative magnetic resonance imaging (qMRI) measures that surpasses sensitivity of joint space narrowing (JSN), an outmoded biomarker of disease progression and clinical outcome, the current regulatory endpoint.

OABP also aims to assess 12 biochemical markers (serum and urine) and correlate with clinical outcome, such as those that are:

The biomarkers being analyzed by OABP were selected after a series of meetings by OARSI, the leading professional society in OA, the U.S. Food and Drug Administration (FDA), and key opinion leaders from the private and public sectors. The consortium will leverage the OAI dataset, a multicenter, longitudinal, prospective, observational study of knee OA.

Structure & Governance

Research for this study will be conducted by an international team of leading OA scientists and clinicians and will utilize the extraordinary resources of OAI. 

Financing

OABP is sponsored by a public-private partnership through the FNIH Biomarkers Consortium.

Data Sharing

Data sharing is coordinated by the partners at the University of California, San Francisco.

Impact/Accomplishment

The potential impact of this project is significant. The OA biomarkers identified may be used to categorize individuals at risk of developing severe OA, to develop new measures for clinical progression of the disease, and to develop new treatment options for the prevention of OA progression.

Points of Contact

Julie Wolf-Rodda
phone: 301-402-6027
email: jwolf-rodda@fnih.org

Sponsors & Partners

Foundation of the National Institutes of Health

GlaxoSmithKline

Memorial Hospital of Rhode Island, Pawtucket

Merck

National Institutes of Health

Novartis

Osteoarthritis Research Society International

Pfizer, Inc.

The Ohio State University

University of California, San Francisco

University of Maryland

University of Pittsburgh


Last Updated: 04/08/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.